89Zr-labeled NY008 PET Imaging in Patients

This is a single arm study to evaluate the safety and biodistribution of 89Zr-labeled NY008 PET Imaging in patients with multiple myeloma

Inclusion Criteria:Older than 18 years old, male or female;Patients diagnosed with relapsing or refractory multiple myeloma；LVEF≥50%；ECOG score 0~2；Exclusion Criteria:Life expectancy of less than 3 months;Participated in other clinical research within 1 month;Recovery from major trauma (including surgery) within 28 days prior to study treatment;Patients with systemic or locally severe infections, or other serious coexisting diseases;Patients with abnormal immune function or who have recently used immunosuppressive or potentiating agents including various vaccines;Patients with autoimmune diseases, including rheumatoid arthritis;Inadequate control of arrhythmias, including atrial fibrillation;Uncontrolled hypertension;Patients with allergies or allergies to any component of the imaging agent or antibody;Patients who cannot undergo PET/CT imaging scan;Syphilis, HBV, HCV, or HIV positive subjects;Male and female subjects of reproductive age cannot take effective contraceptive measures;Pregnant or lactating women;Patients with a history of mental illness or related conditions;Other subjects considered unsuitable by researchers.